POLB vs. SCLP, REDX, ETX, TRX, FARN, AREC, C4XD, SAR, FUM, and OBD
Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Scancell (SCLP), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Faron Pharmaceuticals Oy (FARN), Arecor Therapeutics (AREC), C4X Discovery (C4XD), Sareum (SAR), Futura Medical (FUM), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry.
Poolbeg Pharma (LON:POLB) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership, risk and community ranking.
6.1% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 45.6% of Scancell shares are owned by institutional investors. 22.7% of Poolbeg Pharma shares are owned by insiders. Comparatively, 4.8% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Poolbeg Pharma has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Scancell has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
Poolbeg Pharma's return on equity of -24.00% beat Scancell's return on equity.
Scancell received 187 more outperform votes than Poolbeg Pharma when rated by MarketBeat users.
Poolbeg Pharma has higher earnings, but lower revenue than Scancell. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Scancell, indicating that it is currently the more affordable of the two stocks.
In the previous week, Poolbeg Pharma and Poolbeg Pharma both had 1 articles in the media. Scancell's average media sentiment score of 0.67 beat Poolbeg Pharma's score of 0.00 indicating that Scancell is being referred to more favorably in the news media.
Summary
Poolbeg Pharma and Scancell tied by winning 5 of the 10 factors compared between the two stocks.
Get Poolbeg Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poolbeg Pharma Competitors List
Related Companies and Tools
